obesity-995x60.png
FEATURED ARTICLES
Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
Radioligand therapy (RLT) trials demand specialization. Affibody's Fredrik Frejd explains how they differ in design and execution from standard oncology Phase 1 studies.
-
Two Parallel Trials, A Potential New Option For Protection From COVID-19
Invivyd’s Michael Mina, MD, Ph.D., discusses LIBERTY and DECLARATION, exploring how monoclonal antibodies could expand COVID-19 protection alongside vaccines.
-
Diversity In Clinical Trials Is A Design Decision, Not An Outreach Plan
Build more diverse trials through trusted community ties, physician networks, representative research teams, and intentional site design that support enrollment and retention.
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.